Verapamil and Catamenial Epilepsy

Not Applicable

Withdrawn

• Conditions: Catamenial Epilepsy

• Registration Number: NCT00559169
• Lead Sponsor: University Health Network, Toronto

Brief Summary

One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i.e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2007-11
• Study First Submitted: 2007-11-14
• Study First Submitted QC: 2007-11-14
• Study First Posted: 2007-11-16
• Study Start: 2009-02
• Last Update Submitted: 2010-04-07
• Last Update Posted: 2010-04-08
• Study Completion: 2010-12

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: 12

Inclusion Criteria

• females
• at least 2 seizures per month
• more than 50% of the seizures occur 7 days before or 7 days after the onset of menses
• patient of the Toronto Western Hospital Epilepsy Clinic

Read More

Exclusion Criteria

• cardiovascular history

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
the percent reduction in seizure frequency	3 months

Trial Locations

Locations (1)

Toronto Western Hospital; 🇨🇦 Toronto, Ontario, Canada